June 28, 2024 -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki. Dianthus Presentations at EAN:
June 29, 2024, 14:10 EEST
DNTH103, a Potentially Safer and More Convenient Novel Therapy for Generalised Myasthenia Gravis
June 30, 2024, 14:25 EEST
DNTH103: Preventing Nerve Damage in a CIDP Model via Sustained Complement Inhibition
Session: Muscle and Neuromuscular Junction Disorder 2; Presentation Number: EPR-243
These posters will be made available in the Scientific Publications section of the Dianthus website after they are presented.
“Currently, therapies for patients with generalized Myasthenia Gravis (gMG) are limited to C5 inhibitors or FcRn inhibitors that can be burdensome for patients and caregivers, and the C5 complement inhibitors available today have an increased risk for serious bacterial infections. Similarly, treatment options for patients with CIDP have traditionally been limited to intravenous or subcutaneous infusions of Ig,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “We aim to demonstrate that DNTH103 may become a best-in-class classical complement pathway inhibitor with infrequent self-administration that provides effective and consistent control of symptoms for people living with neuromuscular conditions, without inhibiting the alternative and lectin pathways that are critical in the defense against infection.” DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. DNTH103 is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, self-administered injection dosed as infrequently as once every two weeks. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, DNTH103 has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Dianthus is building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis in 1Q’24, regulatory clearance for Multifocal Motor Neuropathy in 2Q’24, and planned initiation of a Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy in 2H’24. About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
The content above comes from the network. if any infringement, please contact us to modify.